BACKGROUND & AIMS:
Incidence of and mortality from pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, are almost equivalent, so better treatments are needed. We studied gene expression profiles of PDACs and the functions of genes with altered expression to identify new therapeutic targets. METHODS : We performed microarray analysis to analyze gene expression profiles of 195 PDAC and 41 non-tumor pancreatic tissue samples. We undertook an extensive analysis of PDAC transcriptome by superimposing interaction networks of proteins encoded by aberrantly expressed genes over signaling pathways associated with PDAC development to identify factors that might alter regulation of these pathways during tumor progression. We performed tissue microarray analysis to verify changes in expression of candidate protein using an independent set of 152 samples (40 nontumor pancreatic tissues, 63 PDAC sections, and 49 chronic pancreatitis samples). We validated the functional relevance of the candidate molecule using RNA interference or pharmacologic inhibitors in pancreatic cancer cell lines and analyses of xenograft tumors in mice. RESULTS: In an analysis of 38,276 human genes and loci, we identified 1676 genes that were significantly up-regulated and 1166 genes that were significantly down-regulated in PDAC compared with nontumor pancreatic tissues. One gene that was up-regulated and associated with multiple signaling pathways that are dysregulated in PDAC was G protein subunit ai2, which has not been previously associated with PDAC. G protein subunit ai2 mediates the effects of dopamine receptor D2 (DRD2) on cyclic adenosine monophosphate signaling; PDAC tissues had a slight but significant increase in DRD2 messenger RNA. Levels of DRD2 protein were substantially increased in PDACs, compared with non-tumor tissues, in tissue microarray analyses. RNA interference knockdown of DRD2 or inhibition with pharmacologic antagonists (pimozide and haloperidol) reduced proliferation of pancreatic cancer cells, induced endoplasmic reticulum stress and apoptosis, and reduced cell migration. RNA interference knockdown of DRD2 in pancreatic tumor cells reduced growth of xenograft tumors in mice, and administration of the DRD2 inhibitor haloperidol to mice with orthotopic xenograft tumors reduced final tumor size and metastasis. CONCLUSIONS: In gene expression profile analysis of PDAC samples, we found the DRD2 signaling pathway to be activated. Inhibition of DRD2 in pancreatic cancer cells reduced proliferation and migration, and slowed growth of xenograft tumors in mice. DRD2 antagonists routinely used for management of schizophrenia might be tested in patients with pancreatic cancer.
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T he overall 5-year survival rate of all cancer patients stands at 63%, and only about 5% for pancreatic cancer-a number that has remained largely unchanged for the last 3 decades. 1 Of the patients diagnosed with pancreatic cancer, approximately 85% exhibit pancreatic ductal adenocarcinoma (PDAC); most of them die within 6 months after diagnosis. The poor prognosis is caused by a lack of apparent symptoms early during the disease and consequently its detection at only late stages. This goes along with an aggressive tumor biology, in particular, very early metastasis. Finally, effective options for chemotherapy are lacking. 2 The widely used chemotherapeutic agent gemcitabine confers a median survival advantage of only 6 months, 3 also because the vast majority of patients develop resistance to therapy. 4 Given this poor prospect, there is an urgent need for effective treatment modalities. To this end, we set out to investigate potential therapeutic targets by dissecting gene expression profiles of tumors and control samples. Candidate targets were validated with respect to their suitability and analyzed functionally. Using this approach, dopamine receptor D2 (DRD2) was found as a novel, promising protein for the development of a targeted therapy. We show that DRD2 has a central role in proliferation and survival of pancreatic cancer cells. Pharmacologic blockade of DRD2 activity with inhibitors, including the Food and Drug Administration (FDA)À approved DRD2 antagonists pimozide and haloperidol, suppressed the proliferation of pancreatic cancer cells, while having a markedly attenuated effect on normal fibroblasts. Further functional assays demonstrated substantial effects on migration, cell cycle progression and apoptosis as well, providing a broad therapeutic spectrum, and revealed the pathways and mechanisms involved in these processes.
Material and Methods
Detailed information describing methods used in each of the following sections are provided in the Supplementary Material.
Tissue RNA Profiling
The study was performed with tissue samples obtained from patients admitted to the Department of General, Visceral and Transplantation Surgery, University of Heidelberg and the National Institute for Health Research, Liverpool. The study was conducted in accordance with the Helsinki Declaration; written informed consent was obtained from all patients; ethical approval was obtained from the ethical committee of the University of Heidelberg (case number 301/2001). Total RNA from individual samples was analyzed on the Sentrix Human-6v3 Whole Genome Expression BeadChips (Sentrix Human WG-6; Illumina) as suggested by the manufacturer. Information about clinical annotations of samples, isolation of RNA, and microarray expression data analysis, as well as downstream pathway and network analysis, are provided in Supplementary  Table 1 and Supplementary Material.
Cell Lines and Reagents
Five pancreatic cancer cell lines with various degree of differentiation were obtained from the American Type Culture Collection (Manassas, VA). The moderately differentiated BxPC-3 cells, as well as the poorly differentiated cell lines Panc-1 and MiaPaCa-2, originated from primary tumor. The well-differentiated cell lines Capan-1 and CFPAC-1 were isolated from liver metastases of pancreas adenocarcinoma. Normal human dermal fibroblasts were obtained from PromoCell (Heidelberg, Germany). Pimozide, L-741,626, haloperidol, thapsigargin, SQ22536, and H-89 were purchased from Sigma-Aldrich (Munich, Germany).
Plasmids and Viral Transduction
All lentiviral short hairpin RNA (shRNA) vectors were obtained from the Mission TRC genome-wide shRNA collection of Sigma-Aldrich. Additional information about the shRNA vectors can be found at http://www.broad.mit.edu/genome_ bio/trc/rnai.html using the TRCN number. The following lentiviral shRNA vectors targeting DRD2 or ATF4 were used:TRCN0000011342 (shDRD2#1), TRCN0000011343 (shDRD2#2), TRCN0000013573 (shATF4#1), and TRCN0000013575 (shATF4#2). Vector pLKO.1 was used as negative control. Lentivirus production is described in the Supplementary Material.
Quantitative Real-Time Polymerase Chain Reaction
For mice xenograft tissue samples and cultured cells, the miRNeasy kit (Qiagen, Valencia, CA) was used to extract total RNA. Reverse transcription was done using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientific Rockford, Logan, UT). Real-time polymerase chain reaction was run using the ViiA 7 Real-Time PCR System (Applied Biosystems, Darmstadt, Germany) and the FastStart Universal SYBR Green Master Mix (Roche Diagnostics, Mannheim, Germany) according to the manufacturers' specifications. Relative messenger RNA levels of DRD2 were normalized to the expression of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase. Quantification values were calculated according to a standard curve method created from a dilution series. Polymerase chain reactions were performed in triplicate.
Western Blot Analysis
Western blot analysis was performed as described previously. 5 Detailed procedure and antibodies are described in the Supplementary Material.
Colony-Formation Assay
Single-cell suspensions of the indicated parental or transduced pancreatic cancer cell lines were plated in 6-well plates (2-4 Â 10 4 cells/well), and were cultured for 12-15 days while growth medium was refreshed every 4 days. Cells were then washed with phosphate-buffered saline, fixed with paraformaldehyde, stained with crystal violet (0.1% w/v; Sigma-Aldrich) and photographed. Assays were performed independently at least 3 times.
Measurement of the Free Ca 2þ

Concentration in Cytosol
Intracellular Ca 2þ levels were measured using the Fluo-4 NW Calcium Assay Kit (Invitrogen, Karlsruhe, Germany) according to the manufacturer's protocol.
Fluorescence-Activated Cell Sorting Cell Cycle Analysis
Cancer cells were plated into the wells of 12-well plates (NUNC, Roskilde, Denmark) and allowed to grow for 24 hours. Drug treatment was performed for 48 hours with different concentrations. Cells were harvested by trypsinization and washed with cold phosphate-buffered saline. Cold Nicoletti buffer was used for staining and the DNA content of single nuclei was analyzed by flow cytometry on a FACSCANTO II analyzer (BD Biosciences, Heidelberg, Germany) with collection of at least 10,000 events for each sample and in 3 independent experimental repetitions.
Cell Viability
Sulforhodamine B sodium salt (Sigma-Aldrich) assay was used to assess cell viability.
Caspase 3/7 Activity
The cell apoptosis caused by DRD2 antagonists was determined using the Caspase-Glo 3/7 Assay kit (Promega, Madison, WI) according to the manufacturer's instructions.
In Vivo Experiments
Severe combined immunodeficient beige mice were bred in-house. One million Panc-1 cell transduced with shDRD2#1, shDRD2#2, or pLKO were suspended in 150 mL phosphatebuffered saline and mixed with 150 mL Matrigel (BD Biosciences, San Jose, CA) before the respective suspension was injected subcutaneously into the left and right flank of a mouse. For each test cell line, 3 mice were injected with cells in both flanks. Tumor size was determined twice a week using a caliper to measure the volume of the tumor according to the formula: volume (V) ¼ length (L) Â depth (D) Â width (W). After reaching the appropriate volume, primary tumors were resected. In case of pLKO, this happened on day 51 after injection; for shDRD2#1 and shDRD2#2 the tumor was removed after 65 days. Tumors were embedded in paraffin after zinc fixation for immunohistochemistry and H&E staining, or stored at À80 C for RNA extraction.
Two million MIAPaCa-2 cells resuspended in 10 UL Matrigel (BD Biosciences, San Jose, CA) were orthotopically implanted into the tail of the pancreas of 6-week-old Nod scid gamma animals (Jackson Labs, Bar Harbor, ME) (day 1). When tumors were palpable (day 27), mice were randomized into 2 groups (n ¼ 
Statistical Analysis
GraphPad Software 6 for Windows (GraphPad, San Diego, CA), SigmaPlot 12.5 (Systat Software, San Jose, CA) and Microsoft Excel 2010 (Redmond, WA) were used for statistical analysis and graph creation. Data are presented as mean SE from 3-8 independent experiments, depending on the assay. An analysis of difference between the mean of 2 data sets was carried out using the nonparametric MannWhitney U test. P values <.05 were considered as statistically significant.
Results
Gene Expression Profiling Identifies Pancreatic Ductal AdenocarcinomaÀAssociated Pathways
We examined the expression profiles of 38,276 human genes and loci across pancreatic tissue samples from 195 PDAC patients and 41 healthy control subjects (Table 1 and  Supplementary Table 1 ; the complete data set is accessible at the public ArrayExpress database [E-MTAB-1791]). This analysis revealed widespread deregulation of gene expression in PDAC, including 1676 and 1166 genes that were substantially up-or down-regulated in PDAC, respectively (false discovery rate <0.01, Supplementary Table 2) . Interestingly, we found that many up-regulated genes were associated with several cancer-related pathways according to the Kyoto Encyclopedia of Genes and Genomes 6 data sets, with the most significant association corresponding to "pathways in cancer" (P < 5 Â 10 À9 ; Figure 1A and Supplementary Table 3) . Many of the genes associated with "pathways in cancer" were also linked to other PDACenriched processes ( Figure 1B ), suggesting a central role for these "multipathway" genes as potential functional hubs contributing to PDAC. This was further supported by several previous studies
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that reported a connection between these genes and pancreatic cancer (Figure 1B and Supplementary  Table 4 ), highlighting the notion that many of these multipathway genes are reproducibly linked to PDAC.
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, fold-change >2) and its association with 9 PDAC-related pathways. GNAI2 is an a subunit of the guanine nucleotidebinding proteins (G proteins) and primarily functions in G-protein coupled receptor (GPCR) signaling by regulation of adenylate cyclase. 7 In addition, we observed that GNAI2 interacts with several genes that were up-regulated in PDAC, particularly other proteins of the GPCR and cyclic adenosine monophosphate (cAMP pathways) ( Figure 1C ), further supporting its role as a functional signaling hub in PDAC.
GNAI2 Interacting Partner Dopamine Receptor D2 Is Up-Regulated in Pancreatic Ductal Adenocarcinoma
GNAI2 couples cell surface receptors to intracellular pathways, primarily to cAMP signaling. 8 In order to identify cell surface receptors that may take advantage of GNAI2 up-regulation to exert their oncogenic activities in PDAC, we Table 4 for a list of publications related to each gene). (C) GNAI2, as the top multipathway candidate for pancreatic cancer that has not been previously implicated, directly interacts with several other PDAC de-regulated proteins, the majority of which are also up-regulated. Most interactions are with other components of the GPCR signaling pathway. Among the up-regulated interacting partners in this signaling pathway, DRD2 is an aberration hub, with a significant proportion of its first and second-degree neighbors being up-regulated in PDAC samples. Other aberration hubs are also identified by their names. (D) Immunohistochemical analysis of DRD2 protein levels in PDAC samples on tissue microarrays. Representative examples of DRD2 expression in duct cells of normal pancreas, CP and PDAC are shown. Normal ductal cells were almost DRD2-negative or showed a mild positivity in pancreatic ducts. CP lesions and PDACs represented moderate/strong and strong DRD2 expression, respectively. Sizing bar indicates 100 mm. (E) The staining intensity was categorized into 4 groups: <1 ¼ no or poor staining (negative); 1 ¼ weak staining; 2 ¼ moderate staining; and 3 ¼ strong staining. The distribution of DRD2 expression in the clinical tissue samples revealed its high expression in PDAC (P < 10 À13 ) and CP (P < 10
À6
) as compared with normal tissues. P values were calculated by Student t test. 361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420   421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480 systematically looked for "aberration hubs" among the interacting partners of GNAI2 that were up-regulated in PDAC. An aberration hub is defined as a protein that exhibits an unexpectedly large number of physical or functional interactions with "aberrant" proteins; in this case proteins that are significantly up-regulated in PDAC (see Materials and Methods). Aberration hubs often highlight proteins that are central in disease modules. 9 We identified 6 significant aberration hubs among the interacting partners of GNAI2 that are involved in GPCR signaling (false discovery rate <0.01, Figure 1C) . One of them is DRD2, which uses GNAI2 to regulate the cAMP-signaling pathway, the deregulation of which is intrinsic to pancreatic cancer. 10 However, in PDAC samples, the microarray analysis only identified a slight, although very significant, increase in DRD2 messenger RNA levels (1.08-fold; P < .0002). This initially suggested that low levels of DRD2 could act as a bottleneck in this pathway, therefore, limiting the effect of GNAI2 up-regulation. However, tissue microarray analysis of DRD2 across 40 normal pancreatic tissues, 63 PDAC sections, and 49 samples of chronic pancreatitis (CP), an inflammation of the pancreas associated with high risk of PDAC 11 (Supplementary Table 5 ), revealed that DRD2 protein levels were significantly increased in PDAC and CP compared with normal samples (>3-fold), with the highest level detected in PDAC (>4-fold, P < 10 À13 , Figure 1D and E). These results mirrored up-regulation of GNAI2 in PDAC and suggested that DRD2 up-regulation, most likely due to a post-transcriptional aberration, may contribute to malignancy. 481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540   541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598 599 600
BASIC AND TRANSLATIONAL PANCREAS
Silencing of Dopamine Receptor D2 Inhibits Cancer Cell Growth in Vitro and in Vivo
To determine whether DRD2 contributes to tumor cell growth and survival, we suppressed DRD2 expression in the pancreatic cancer cell lines Panc-1 and MiaPaCa-2 through lentiviral delivery of expression vectors of shRNAs targeting DRD2. Knockdown of DRD2 expression by 2 independent shRNA constructs impaired proliferation of both cell lines as measured by a long-term colony-formation assay (Figure 2A and Supplementary Figure 1A) .
For confirmation in vivo, we subcutaneously injected 1 Â 10 6 Panc-1 cells expressing either of the 2 shRNAs targeting DRD2 or the pLKO control into severe combined immunodeficient beige mice, with 2 replicates, and monitored tumor size over time. Mice implanted with pLKOexpressing cells developed tumors much earlier (21.7 ± 1.6 days) than those engrafted with DRD2-deficient cells (33. 601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616  617  618  619  620  621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645  646  647  648  649  650  651  652  653  654  655  656  657  658  659  660   661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683  684  685  686  687  688  689  690  691  692  693  694  695  696  697  698  699  700  701  702  703  704  705  706  707  708  709  710  711  712  713  714  715  716  717  718  719  720 with the control group (P <.002, Figure 2B ), while there was no significant difference in body weight between control and test groups (Supplementary Figure 1B) . Immunohistochemical analysis of the tumors confirmed the reduced levels of DRD2 in tissues isolated from animals treated with DRD2-deficient cells compared with the controls (Figure 2C and D), in line with lower DRD2 messenger RNA levels in tumors developed from DRD2-deficient cells as assayed by quantitative reverse transcription polymerase chain reaction (Supplementary Figure 1C) . Concomitant to the reduction in DRD2, protein Ki-67-a marker of cell proliferation
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-was markedly reduced (Figure 2C and D) . These results demonstrated that DRD2 has a key role in proliferation and survival of tumor cells.
Pharmacologic Blockade of Dopamine Receptor D2 Impairs Cancer Cell Growth
We examined the effect of pharmacologic inhibition of DRD2 on cancer cell proliferation. Different concentrations of the DRD2 antagonist pimozide, an FDA-approved DRD2 inhibitor used for treatment of schizophrenia, 13 were tested on 5 established pancreatic cancer cell lines-Panc-1, CFPAC-1, Capan-1, MiaPaCa-2, and BxPC-3. Treatment with pimozide resulted in a dose-dependent inhibitory effect on cell growth in all examined cell lines. Notably, the pimozide effect was stronger in MiaPaCa-2 and BxPC-3 cells, which showed higher expression levels of DRD2 among the cell lines, and weaker on a primary normal fibroblast cell line used as a control ( Figure 3A) . We repeated the assay with another DRD2 inhibitor, L-741,626 (L-741).
14 L-741 treatment had virtually the same effect (Supplementary Figure 2A) . Taken together, our results demonstrated that pharmacologic blockade of DRD2 activity inhibits proliferation of pancreatic cancer cells.
Induction of Endoplasmic Reticulum Stress in Response to Dopamine Receptor D2 Blockade
Deficiency of DRD2 leads to endoplasmic reticulum (ER) stress, 15 the severe form of which has anti-proliferative and pro-apoptotic effects in cancer cells. 16 We examined the possible effect of DRD2 blockade on induction of ER stress by evaluating the level of phosphorylated PERK (Thr 981). Pimozide increased phosphorylation of PERK in a dosedependent manner in both Panc-1 and MiaPaCa-2 cells, as determined by immunoblotting ( Figure 3B ). Similar results were obtained by treating cells with L-741 (Supplementary Figure 2B) . As ER stress is coupled to the release of Ca 2þ from the ER into the cytosol, 17 we examined whether DRD2 inhibition would affect the cytosolic abundance of Ca 2þ . Indeed, treatment with both pimozide and L-741 increased the concentration of cytosolic Ca 2þ within seconds in Panc-1 and MiaPaCa-2 ( Figure 3C) , showing that DRD2 blockade induces ER stress in PDAC cells.
Cyclic Adenosine Monophosphate and Protein Kinase A Mediates the Effects of Dopamine Receptor D2 Inhibition on Endoplasmic Reticulum Stress
It has been shown that cAMP and protein kinase A (PKA) regulate Ca 2þ levels in the cytosol and are involved in ER stress. 18, 19 It has also been reported that DRD2 modulates intracellular cAMP formation. 20 Accordingly, we examined whether induction of ER stress by DRD2 blockade would be mediated by cAMP and PKA. To this end, the activity of PKA, which is dependent on the presence of cAMP, was measured through Western blot analysis using a phospho-PKA substrate antibody in Panc-1 and MiaPaCa-2 cells following treatment with pimozide. Activation of PKA was detected upon incubation with 1 mM pimozide. The effect grew stronger with the administration of higher drug concentrations ( Figure 3D ), indicating that cAMP/PKA is activated in a dose-dependent manner upon inhibition of DRD2.
In order to examine whether the ER stress induced by DRD2 inhibition is influenced by modulation of cAMP or PKA, Panc-1 cells were pretreated with SQ22536, a specific cAMP inhibitor, to down-regulate cAMP and PKA activation; alternatively, the drug H-89 21 was used to block PKA. Strikingly, the pimozide-induced release of Ca 2þ from the ER to cytoplasm was completely blocked or substantially reduced by a pretreatment with SQ22536 or H-89, respectively ( Figure 3E ). The stronger reduction of Ca 2þ levels by SQ22536 may be explained by the finding that cAMP affects all calcium transport system receptors in the ER, whether they are PKA-dependent or not. 18 Together, our findings showed that DRD2 antagonists increase cytosolic levels of Ca 2þ in a rapid and effective manner; the level of cAMP, which acts downstream of DRD2, 22, 23 is increased after the blockade of DRD2; and Ca 2þ levels are positively regulated by cAMP mainly and to a lesser extent by PKA.
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Dopamine Receptor D2 Blockade Impairs Cell Cycle Progression and Induces Apoptosis
Previous studies have shown that ER stress can affect the cell cycle at the G1/S transition via regulating cyclin D1. 24, 25 We therefore investigated the effect of DRD2 inhibition on cell cycle progression. Panc-1 and MiaPaCa-2 cells were treated with different concentrations of Pimozide for 48 hours and their distribution in the cell cycle states was analyzed using fluorescence-activated cell sorting. Pimozide-induced cell cycle arrest at the G1 phase in a dose-dependent manner ( Figure 4A ). In addition, the increase in the fraction of cells in sub-G1 in the fluorescence-activated cell sorting analysis indicated a higher number of apoptotic cells. To verify this, activation of caspase 3/7 was examined 24 hours post-treatment with pimozide. Caspase 3/7 activity grew with increasing pimozide concentrations ( Figure 4A ), confirming that inhibition of DRD2 induces apoptosis in PDAC cells. We further validated the induction of cell cycle arrest at a molecular level by measuring the abundance of cell cycle checkpoint proteins. Consistent with the fluorescenceactivated cell sorting data, Western blot analysis showed a decrease in the cyclin D1, p-Rb, and cyclin E1 levels, and an increase in the levels of p21 and p27 in a dose-dependent manner, confirming G1 cell cycle arrest ( Figure 4B ).
Dopamine Receptor D2 Inhibition Activates Unfolded Protein Response in Pancreatic Cancer Cells
As reported here, the blockade of DRD2 led to phosphorylation and thus activation of PERK, which is a marker of unfolded protein response (UPR). Recent studies have shown that a strong induction of UPR as indicated by PERK activation can lead to UPR-induced apoptosis through phosphorylation of downstream molecule eIF2a and selective induction of ATF4, which in turn increases the expression of CHOP. 26 Therefore, we examined the activity and expression levels of proteins involved in the PERK Q9 arm of UPR after treatment of cells with pimozide ( Figure 4C ). Phosphorylation of eIF2a as well as the expression levels of ATF4 and CHOP increased upon pimozide treatment in a dose-dependent manner, in line with the increase in activated PERK ( Figure 3B ). We further investigated the induction of UPR in DRD2-deficient cells in vivo. In severe combined immunodeficient beige mice, the abundance of phosphorylated eIF2a (p-eIF2a) and CHOP was assessed in tumors that developed after implantation of Panc-1 cells infected with shDRD2 constructs or the pLKO control. Immunohistochemical analysis on tumor samples demonstrated the elevated levels of p-eIF2a and CHOP in tumors developed from DRD2-deficient cells as compared with the control tumors ( Figure 4D ). These findings provide evidence that inhibition of DRD2 triggers UPR. To investigate the extent to which activation of ER-UPR signaling mediates growth inhibitory function of DRD2 blockade, we generated ATF4-deficient sublines of Panc-1 and MiaPaca-2 cells through stable knock-down using 2 specific ATF4-shRNAs (Supplementary Figure 3A and B) , and examined effects of DRD2 inhibition in these models. Likewise, we tested effects of the ER stress inducer, thapsigargin, 27 on cell viability and apoptosis in these cells. Reduction of cell viability and induction of apoptosis after treatment with pimozide or thapsigargin were significantly declined in ATF4-deficient cells compared with control (pLKO) ( Figure 4E and F) . Similar results were obtained after treatment of these cells with L-741 (Supplementary Figure 3CÀF) . These results show that the UPR pathway is an important mediator of growth inhibitory effects of DRD2 blockade.
Blockade of Dopamine Receptor D2 Inhibits Cancer Cell Migration
Our previous results showed that DRD2 regulates the cAMP level, which is known to modulate cell adhesion and motility in pancreatic cancer cells. 10 Consequently, we studied whether DRD2 inhibition has an effect on cancer cell migration by assessing the motility of the highly invasive Panc-1 cells in a wound healing assay in the presence of the DRD2 antagonists pimozide and L-741. Both antagonists reduced migration of Panc-1 cells in a dose-dependent manner using concentrations that did not inhibit cell growth ( Figure 5A and Supplementary Figure 4A and B). Consistent with this result, we observed a gradual rise in the expression of E-cadherin protein and a simultaneous decrease in vimentin levels ( Figure 5B ). To exclude the possibility that the effect of DRD2 inhibition on cell = Figure 4 . Pimozide induces apoptosis and cell cycle arrest at G1 phase in PDAC cells. (A) Left: Panc-1 and MiaPaCa-2 cells were seeded for 24 hours and treated with increasing concentrations of pimozide or DMSO for 48 hours. Cells were fixed and stained with Nicoletti buffer, and cell cycle distribution was analyzed by fluorescence-activated cell sorting. Sub-G1 and G1 cells increased with increasing pimozide concentrations in both Panc-1 (P < .003 and <.001 for sub-G1 and G1, respectively) and MiaPaCa-2 cells (P < 7 Â 10 À4 and < 4 Â 10 À5 for sub-G1 and G1, respectively). Conversely, S-phase cells decreased with higher pimozide concentrations in both Panc-1 and MiaPaCa-2 (P < .003 and <3 Â 10 À5 , respectively; all P values are obtained by regression slope t test). Right: Dose-dependent activation of caspase 3/7 in PDAC cells after treatment with pimozide. Panc-1 and MiaPaCa-2 were exposed to pimozide and DMSO as control for 24 hours. Then, caspase 3/7 activity was measured. migration was specific for the 2-dimensional wound healing assay, we examined the migration of Panc-1 cells by the quantitative 3-dimensional Boyden chamber assay in the presence of pimozide, which confirmed that the treatment suppresses cell migration (Supplementary Figure 4C) . Furthermore, we validated the inhibitory effect of pimozide and L-741 on pancreatic cancer cell migration by testing another cell line (MiaPaCa-2) ( Figure 5C ). In order to verify the involvement of the cAMP/PKA pathway in the observed inhibitory effect of DRD2 blockade, we analyzed cell migration while perturbing this pathway. The reduction in cell migration upon treatment with pimozide or L-741 was rescued by the addition of H89 or SQ22536, which both reduce PKA activation and cAMP levels ( Figure 5D , and Supplementary Figure 4D) . Taken together, these results demonstrated that the DRD2 blockade suppresses pancreatic cancer cell migration by induction of cAMP and activation of PKA.
Blockade of Dopamine Receptor D2 Reduces Tumor Growth and Metastasis in Vivo
We replicated anti-cancer effects of DRD2 inhibition using another FDA-approved DRD2 antagonist haloperidol. 28 Haloperidol treatment showed the same effects as those observed with pimozide and L-741 treatments ( Figure 6AÀE) . Interestingly, however, haloperidol displayed the lowest toxicity on normal fibroblast cells among DRD2 inhibitors examined in our study. Therefore, we set out to verify the anti-cancer effects of haloperidol in orthotopic models of pancreatic cancer, which we generated by implanting MiaPaCa-2 cells into the tail of the pancreas of Nod scid gamma mice. After tumor development, mice were randomized into 2 groups and treated with haloperidol (n ¼ 9) or control solvent (n ¼ 7). Haloperidol treatment (10 mg/kg selected based on results reported for glioblastoma treatment 29 ) reduced tumor volume, weight, and metastatic dissemination significantly (P < .001), while showing no significant effect on animal weight ( Figure 6F ).
Discussion
Investigating novel targeted therapeutic opportunities for PDAC, we applied a combination of pathway-and network-based approaches to PDAC transcriptome profiles. Specifically, we leveraged on identifying aberration hubs by overlaying PDAC-associated gene expression patterns on the human protein interaction network in order to highlight factors with potential driver activities among the plethora of deregulated genes. This led to the identification of DRD2, which we validated as a novel promising therapeutic target. Our findings revealed a high expression of DRD2 in PDAC, and confirmed the efficacy of its blockade to suppress cancer cell proliferation, survival, and metastasis potential. We found that DRD2 blockade has an anti-proliferative effect in pancreatic cancers, while activating ER stress, in line with previous studies reporting that the deficiency of DRD2 induces ER stress. 15 The accelerated proliferation of cancer cells in solid tumors often leads to nutrient deprivation in their microenvironment and results in protein misfolding, which eventually triggers activation of ER stress. 16 Whereas moderate ER stress supports cell survival in nutrient-deprived conditions, excessive ER stress leads to cell cycle arrest and apoptosis, 30, 31 and has emerged as an attractive anti-cancer therapeutic avenue. 32, 33 As such, inhibiting DRD2 provides a targeted approach to activate ER stress in cancer cells.
Importantly, when compared with normal samples, DRD2 expression was elevated significantly in CP, which is a known major risk factor for PDAC, 11 suggesting that DRD2 overexpression may be involved in the early steps of PDAC development. In line with this observation, Sachlos and colleagues 34 have shown that dopamine receptors are overexpressed in human cancer stem cells and that inhibition of dopamine receptor signaling can serve as an effective approach to impair tumorigenicity of cancer stem cells. Notably, both studies utilized DRD2 antagonists that are approved by the FDA as antipsychotic agents (pimozide and haloperidol in our study and thriodazine in Sachlos et al). Interestingly, schizophrenic patients receiving DRD2 ) were orthotopically injected into the tail of the pancreas of NSG mice. Twenty-seven days post-surgery, mice were randomized into 2 groups and treated with either haloperidol (10 mg/kg, intraperitoneal) or vehicle for 12 days. The experiment was terminated when control animals became moribund. Animal weight, tumor weight, and tumor volume were measured at time of sacrifice. Upper panel: Tumor weight (left) and volume (middle) were significantly reduced in mice treated with haloperidol compared with the control group, while there was no significant change in body weight (right) between groups. Bottom panel: Representative images show tumors in mice. White and yellow outlines show primary and metastatic tumors, respectively. Treatment with haloperidol reduced the metastasis dissemination. **P < .01 when compared with the corresponding results at 0 mM in (B), pLKO at 30 mM in (D) or haloperidol at 20 mM in (E) (Mann-Whitney U test). 1201  1202  1203  1204  1205  1206  1207  1208  1209  1210  1211  1212  1213  1214  1215  1216  1217  1218  1219  1220  1221  1222  1223  1224  1225  1226  1227  1228  1229  1230  1231  1232  1233  1234  1235  1236  1237  1238  1239  1240  1241  1242  1243  1244  1245  1246  1247  1248  1249  1250  1251  1252  1253  1254  1255  1256  1257  1258  1259  1260   1261  1262  1263  1264  1265  1266  1267  1268  1269  1270  1271  1272  1273  1274  1275  1276  1277  1278  1279  1280  1281  1282  1283  1284  1285  1286  1287  1288  1289  1290  1291  1292  1293  1294  1295  1296  1297  1298  1299  1300  1301  1302  1303  1304  1305  1306  1307  1308  1309  1310  1311  1312  1313  1314  1315  1316  1317  1318  1319  1320 BASIC AND TRANSLATIONAL PANCREAS
antagonists have a reduced incidence rate of different solid tumors, including those of rectum, colon, and prostate, compared with the general population. 35 Likewise, lower cancer incidence rates have been reported in patients suffering from Parkinson's disease in which the dopaminergic pathway is deficient. 36 These findings suggest that dopaminergic signaling may be involved in the development of multiple cancers, and may potentially serve as a pancancer therapeutic target. Supporting this, DRD2 antagonists have also shown anti-cancer effects in leukemia 34 and glioblastoma. 29 However, other effectors including signal transducer and activator of transcription 5 and extracellular signalÀregulated kinase signaling have been proposed as mediators of DRD2 function in these tumors. Notably, we did not observe a decrease in phosphorylation of signal transducer and activator of transcription 5 or extracellular signalÀregulated kinase in PDAC cells upon treatment with DRD2 antagonists (Supplementary Figure 5) , but validated that the anti-growth effect of pimozide and haloperidol on pancreatic cancer cells is primarily through targeting DRD2 (Supplementary Figure 6) . Given the inherent heterogeneous nature of cancer and the involvement of GPCRs in multiple signaling cascades, 8 it is possible that the functional consequences of DRD2 blockade are mediated through various signaling pathways in different tumors. Additional experiments are warranted to elucidate the exact mechanism of DRD2 inhibition in pancreatic cancer.
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